Clinical trial

Ruxolitinib for Premalignant Breast Disease

NCT02928978

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-05-13

PhasePHASE2

Study timeline

Study start (actual)2018-05-13Date precision: day

Registry last updated2026-04-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Ductal Carcinoma In Situunresolved

Atypical Lobular Hyperplasiaunresolved

Atypical Ductal Hyperplasiaunresolved

Lobular Carcinoma In Situunresolved

Interventions

RuxolitinibDRUG · verified · RxNorm: ruxolitinib

Placebo (for Ruxolitinib)DRUG

Sponsors & collaborators

Julie Nangialead sponsor

Incyte Corporationcollaborator

Translational Breast Cancer Research Consortiumcollaborator

Mapped research locations

HoustonTexas, United States3 NashvilleTennessee, United States1 BirminghamAlabama, United States1 IndianapolisIndiana, United States1 Chapel HillNorth Carolina, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02928978 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.